

July 24, 2017

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001

Scrip code: 532531

The National Stock Exchange of India Limited

Exchange Plaza , Bandra-Kurla Complex
Bandra (E) Mumbai - 400 051

Scrip code: STAR

Dear Sirs,

Sub: Press Release


Please find attached press release issued by the Company titled:


**“Strides Shasun receives USFDA Approval
for Cetirizine Softgel Capsules”**

Thanks & Regards,
For **STRIDES SHASUN LIMITED**



Manjula Ramamurthy
Company Secretary





Press Release

July 24, 2017

Strides Shasun Limited
(Formerly Strides Arcolab Limited)
Strides House, Bannerghatta Road,
Bangalore – 560076.

Strides Shasun receives USFDA Approval for Cetirizine Softgel Capsules

First Indian Generic Company to receive approval for Cetirizine (Softgel)

Bangalore, July 24, 2017 Strides Shasun Limited today announced that it has received approval from the United States Food & Drug Administration (USFDA) for **Cetirizine Hydrochloride Capsules, 10 mg (Liquid Filled Capsules) [OTC]**

According to IRI data, the US market for Cetirizine Hydrochloride Capsules (Softgel) is approximately USD 60 Million, with only one other generic player. The product will be manufactured at the Company's flagship facility at Bangalore and marketed by Strides Pharma Inc. in the US Market. The product is ready for launch immediately and as in the case of OTC products, the market formation takes time and the Company expects to have an important market share in approximately six months.


This is the first approval for a Softgel product after the recent US FDA inspection at the Company's Bangalore facility.

About Cetirizine Hydrochloride Capsules

Cetirizine is an antihistamine used to relieve allergy symptoms such as watery eyes, runny nose, itching eyes/nose, sneezing, hives, and itching. It works by blocking a certain natural substance (histamine) that your body makes during an allergic reaction.

About Strides Shasun Limited

Strides Shasun, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a vertically integrated global pharmaceutical Company headquartered in Bangalore. The Company has four business verticals, viz., Regulated Markets, Emerging Markets, Institutional Business and Active Pharmaceutical Ingredients.



The Company has global manufacturing foot print with 9 manufacturing facilities spread across three continents including 7 US FDA approved facilities and 2 facilities for the emerging markets. The Company has two dedicated R&D facilities in India with global filing capabilities and a strong commercial footprint across 85 countries. Additional information is available at the Company's website at www.stridesarco.com

For further information, please contact:

<u>Strides Shasun</u> Shashank Sinha, Managing Director +91 80 6784 0335 Vikesh Kumar +91 80 6784 0827 Kannan. N: +91 98450 54745 Sandeep Baid: +91 80 6784 0791	<u>PR Consultancy</u> Fortuna PR K Srinivas Reddy: +91 9000527213 srinivas@fortunapr.com K Priya: +91 9535425418 priya@fortunapr.com
--	--

